The cost of diabetes cared an elephant in the room

Diabetes Care

Volumn 41, Issue 5, 2018, Pages 929-932

  Riddle, Matthew C ^a   Herman, William H ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN;

CLINICAL RESEARCH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NOTE; PATIENT CARE; QUALITY OF LIFE; UNITED STATES;

EID: 85046114807     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci18-0012     Document Type: Note

References (24)

1. American Diabetes Association. Economiccosts of diabetes in the U. S.in2002. DiabetesCare 2003;26:917-932
2. American Diabetes Association. Economiccosts of diabetes in the U. S.in2007. Diabetes Care 2008;31:596-615
3. American Diabetes Association. Economiccosts of diabetes in the U. S.in2012. Diabetes Care 2013;36:1033-1046
4. American Diabetes Association. Economiccosts of diabetes in the U. S.in2017. Diabetes Care 2018;41:917-928
5. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723-730
6. Moin T, Li J, Duru OK, et al. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med 2015;162:542-548
7. Siminerio LM, Albright A, Fradkin J, et al. The National Diabetes Education Program at 20 years: lessons learned and plans for the future. Diabetes Care 2018;41:209-218
8. Ely EK, Gruss SM, Luman ET, et al. A national efforttoprevent type2diabetes: participant-level evaluation of CDC's National Diabetes Prevention Program. Diabetes Care 2017;40:1331-1341
9. Herman WH, Pan Q, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Impact of lifestyleandmet for mininterventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care 2017;40:1668-1677
10. Selvin E, Ali MK. Declines in the incidence of diabetes in the U. S.dreal progress or artifact? Diabetes Care 2017;40:1139-1143
11. Gregg EW. The changing tides of the type 2 diabetes epidemicdsmooth sailing or troubled waters ahead? Kelly West Award Lecture 2016. Diabetes Care 2017;40:1289-1297
12. Rubens M, Saxena A, Ramamoorthy V, et al. Trends in diabetes-related preventable hospitalizations in the U. S., 2005-2014. Diabetes Care 2018;41:e72-e73
13. Berkowitz SA, Kalkhoran S, Edwards ST, Essien UR, Baggett TP. Unstable housing and diabetesrelated emergency department visits and hospitalization: a nationally representative study of safety-net clinic patients. Diabetes Care 2018;41:933-939
14. Wharam JF, Zhang F, Eggleston EM, Lu CY, Soumerai SB, Ross-Degnan D. Effect of highdeductible insurance on high-acuity outcomes in diabetes: a Natural Experiment for Translation in Diabetes (NEXT-D) Study. Diabetes Care 2018;41:940-948
15. Puckrein GA, Nunlee-Bland G, Zangeneh F, et al. Impactof CMS Competitive Bidding Program on Medicare beneficiary safety and access to diabetes testing supplies: a retrospective, longitudinal analysis. Diabetes Care 2016;39:563-571
16. Puckrein GA, Hirsch IB, Parkin CG, Taylor BT, Xu L, Marrero DG. Impact of the 2013 national rollout of CMS Competitive Bidding Program: the disruption continues. Diabetes Care 2018;41:949-955
17. Casagrande SS, McEwen LN, Herman WH. Changes in health insurance coverage under the Affordable Care Act: a national sample of U. S. adults with diabetes, 2009 and 2016. Diabetes Care 2018;41:956-962
18. Nuckols TK, Keeler E, Anderson LJ, et al. Economic evaluation of quality improvement interventions designed to improve glycemic control in diabetes: asystematic reviewand weighted regression analysis. Diabetes Care 2018;41:985-993
19. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectivenessdthe curious resilience of the $50, 000-per-QALY threshold. N Engl J Med 2014;371:796-797
20. Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 2018;41:963-970
21. Kähm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated within cident complications inpatients withtype 2 diabetes in Germany. Diabetes Care 2018;41:971-978
22. Magliano DJ, Martin VJ, Owen AJ, Zomer E, Liew D. The productivity burden of diabetes at a population level. Diabetes Care 2018;41:979-984
23. Wan E Y F, Fung C S C, Jiao FF, et al. Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service usesda populationbased and propensity-matched cohort study. Diabetes Care 2018;41:49-59
24. Jiao FF, Fung C S C, Wan E Y F, et al. Five-yearcost effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM). Diabetes Care 2018;41:250-257